<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210157/" ref="ordinalpos=1660&amp;ncbi_uid=3403850&amp;link_uid=PMC3210157" image-link="/pmc/articles/PMC3210157/figure/pone-0027318-g008/" class="imagepopup">Figure 8. Hypothetical model of 16K hPRL effects on Notch <span class="highlight" style="background-color:">signaling</span> in endothelial/pericyte interactions..  From: The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. </a></div><br /><div class="p4l_captionBody">When endothelial cells are cultured with pericytes, Dll4/Notch4 pathway is activated. 16K hPRL treatment (6 h) alters Dll4/Notch4 signaling by decreasing DLL4, NOTCH4, HEY2 and EPHRINB2 transcripts in endothelial cells. After 16 h of endothelial cell-pericyte cocultures, Notch3 and Dll1 are increased respectively in pericytes and endothelial cells. 16K hPRL inhibits the Dll1/Notch3 signaling by reducing DLL1 transcripts in endothelial cells and NOTCH3 and aSMA transcripts in pericytes.</div></div>